READ THE FULL CCLD RESEARCH REPORT
CareCloud (NASDAQ: CCLD) had a productive quarter with the elimination of the Series B Preferred and replacing it with tax-deductible and lower-cost debt. This should be a big benefit to common shareholders in both cost and a simplified, understandable balance sheet. During the quarter, the company acquired Empower Healthcare and Compliance Partners, adding full-service healthcare compliance and advisory to its offerings and adding another cross-selling opportunity.
The company has had success with its new AI products.
CirrusAI is CareCloud’s AI-powered solution for real-time clinical documentation that turns complex patient data into actionable insights.
StratusAI is CareCloud’s completely customizable 24/7 front desk agent that instantly turns missed calls into captured revenue while the customer can focus on more complex issues and delivering exceptional in-office care.
Coming later this year are three new products as shown below. The company is alpha testing these in their own service operations, and all have shown meaningful savings and accuracy.
While investors may have thought CareCloud’s Q2 results were weak, Q3 should show the typical strong seasonality combined with a full quarter of the preferred redemption. With revenue growth, a forecasted return to earnings growth, and a low valuation, this could be a good entry point in the stock.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
